α-lipoic acid protects dopaminergic neurons against MPP +-induced apoptosis by attenuating reactive oxygen species formation

International Journal of Molecular Medicine

Volumn 32, Issue 1, 2013, Pages 108-114

  Li, Da Wei ^a   Li, Guang Ren ^a   Lu, Yan ^a   Liu, Zhi Qiang ^a   Chang, Ming ^a   Yao, Ming ^a   Cheng, Wei ^a   Hu, Lin Sen ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

lipoic acid; 1 methyl 4 phenylpyridinium; Apoptosis; Neuroprotection; Parkinson's disease; Reactive oxygen species

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID;

APOPTOSIS; ARTICLE; ATTENUATION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PC12 CELL; PRIORITY JOURNAL;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL SURVIVAL; DOPAMINERGIC NEURONS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEUROPROTECTIVE AGENTS; PC12 CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; REACTIVE OXYGEN SPECIES; THIOCTIC ACID;

EID: 84878214483     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1361     Document Type: Article

References (54)

1. Fleury C, Mignotte B and Vayssiere JL: Mitochondrial reactive oxygen species in cell death signaling. Biochimie 84: 131-141, 2002. (Pubitemid 34946949)
2. Jenner P: Oxidative stress in Parkinson's disease. Ann Neurol 53 (Suppl 3): S26-S38, 2003.
3. Hatanaka H: Nerve growth factor-mediated stimulation of tyrosine hydroxylase activity in a clonal rat pheochromocytoma cell line. Brain Res 222: 225-233, 1981.
4. Rebois RV, Reynolds EE, Toll L and Howard BD: Storage of dopamine and acetylcholine in granules of PC12, a clonal pheochromocytoma cell line. Biochemistry 19: 1240-1248, 1980. (Pubitemid 10033206)
5. Langston JW and Irwin I: MPTP: current concepts and controversies. Clin Neuropharmacol 9: 485-507, 1986. (Pubitemid 17217320)
6. Kopin IJ and Markey SP: MPTP toxicity: implications for research in Parkinson's disease. Annu Rev Neurosci 11: 81-96, 1988. (Pubitemid 18081034)
7. Heikkila RE, Sieber BA, Manzino L and Sonsalla PK: Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 10: 171-183, 1989. (Pubitemid 19204705)
8. Calon F, Lavertu N, Lemieux AM, et al: Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter. Synapse 40: 225-234, 2001. (Pubitemid 32322215)
9. Chiba K, Trevor A and Castagnoli N Jr: Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574-578, 1984. (Pubitemid 14101750)
10. Javitch JA, D'Amato RJ, Strittmatter SM and Snyder SH: Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173-2177, 1985. (Pubitemid 15056491)
11. Hartley A, Stone JM, Heron C, Cooper JM and Schapira AH: Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 63: 1987-1990, 1994. (Pubitemid 24326248)
12. Packer L, Witt EH and Tritschler HJ: Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 19: 227-250, 1995.
13. Packer L, Tritschler HJ and Wessel K: Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 22: 359-378, 1997.
14. Bustamante J, Lodge JK, Marcocci L, Tritschler HJ, Packer L and Rihn BH: Alpha-lipoic acid in liver metabolism and disease. Free Radic Biol Med 24: 1023-1039, 1998. (Pubitemid 28186244)
15. Han D, Tritschler HJ and Packer L: Alpha-lipoic acid increases intracellular glutathione in a human T-lymphocyte Jurkat cell line. Biochem Biophys Res Commun 207: 258-264, 1995.
16. Bast A and Haenen GR: Interplay between lipoic acid and glutathione in the protection against microsomal lipid peroxidation. Biochim Biophys Acta 963: 558-561, 1988. (Pubitemid 19002590)
17. Busse E, Zimmer G, Schopohl B and Kornhuber B: Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung 42: 829-831, 1992.
18. Hagen TM, Ingersoll RT, Lykkesfeldt J, et al: (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 13: 411-418, 1999. (Pubitemid 29072418)
19. Packer L, Kraemer K and Rimbach G: Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 17: 888-895, 2001. (Pubitemid 33001657)
20. Yilmaz O, Ozkan Y, Yildirim M, Ozturk AI and Ersan Y: Effects of alpha lipoic acid, ascorbic acid-6-palmitate, and fish oil on the glutathione, malonaldehyde, and fatty acids levels in erythrocytes of streptozotocin induced diabetic male rats. J Cell Biochem 86: 530-539, 2002. (Pubitemid 36076170)
21. Wollin SD and Jones PJ: Alpha-lipoic acid and cardiovascular disease. J Nutr 133: 3327-3330, 2003.
22. McNeilly AM, Davison GW, Murphy MH, et al: Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance. Lipids Health Dis 10: 217, 2011.
23. Ziegler D, Hanefeld M, Ruhnau KJ, et al: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 38: 1425-1433, 1995.
24. Ziegler D, Hanefeld M, Ruhnau KJ, et al: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22: 1296-1301, 1999. (Pubitemid 29350240)
25. Andreyev AY, Kushnareva YE and Starkov AA: Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc) 70: 200-214, 2005. (Pubitemid 40512329)
26. Turrens JF: Mitochondrial formation of reactive oxygen species. J Physiol 552: 335-344, 2003.
27. Balaban RS, Nemoto S and Finkel T: Mitochondria, oxidants, and aging. Cell 120: 483-495, 2005. (Pubitemid 40269763)
28. Adam-Vizi V and Chinopoulos C: Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci 27: 639-645, 2006. (Pubitemid 44767940)
29. Brookes PS: Mitochondrial H(+) leak and ROS generation: an odd couple. Free Radic Biol Med 38: 12-23, 2005.
30. Kussmaul L and Hirst J: The mechanism of superoxide production by NADH: ubiquinone oxidoreductase (complex I) from bovine heart mitochondria. Proc Natl Acad Sci USA 103: 7607-7612, 2006.
31. Sipos I, Tretter L and Adam-Vizi V: Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals. J Neurochem 84: 112-118, 2003. (Pubitemid 36182071)
32. Dauer W and Przedborski S: Parkinson's disease: mechanisms and models. Neuron 39: 889-909, 2003. (Pubitemid 37130207)
33. Przedborski S, Jackson-Lewis V, Djaldetti R, et al: The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16: 135-142, 2000. (Pubitemid 30159159)
34. Kataoka H: Chromatographic analysis of lipoic acid and related compounds. J Chromatogr B Biomed Sci Appl 717: 247-262, 1998.
35. Smith AR, Shenvi SV, Widlansky M, Suh JH and Hagen TM: Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 11: 1135-1146, 2004. (Pubitemid 38585058)
36. Scott BC, Aruoma OI, Evans PJ, et al: Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Radic Res 20: 119-133, 1994. (Pubitemid 24103740)
37. Liu J, Head E, Gharib AM, et al: Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci USA 99: 2356-2361, 2002. (Pubitemid 34169065)
38. Han D, Sen CK, Roy S, Kobayashi MS, Tritschler HJ and Packer L: Protection against glutamate-induced cytotoxicity in C6 glial cells by thiol antioxidants. Am J Physiol 273: R1771-R1778, 1997. (Pubitemid 27518131)
39. Droge W: Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
40. Reddy PH: Mitochondrial medicine for aging and neurodegenerative diseases. Neuromol Med 10: 291-315, 2008.
41. Beal MF: Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58: 495-505, 2005.
42. Lin MT and Beal MF: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795, 2006. (Pubitemid 44622683)
43. Reddy PH, Mao P and Manczak M: Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res Rev 61: 33-48, 2009.
44. Selvaraj S, Watt JA and Singh BB: TRPC1 inhibits apoptotic cell degeneration induced by dopaminergic neurotoxin MPTP/MPP(+). Cell Calcium 46: 209-218, 2009.
45. Abou-Sleiman PM, Muqit MM and Wood NW: Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7: 207-219, 2006. (Pubitemid 43292466)
46. Shiba-Fukushima K, Imai Y, Yoshida S, et al: PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. Sci Rep 2: 1002, 2012.
47. Lee BW, Kwon SJ, Chae HY, et al: Dose-related cytoprotective effect of alpha-lipoic acid on hydrogen peroxide-induced oxidative stress to pancreatic beta cells. Free Radic Res 43: 68-77, 2009.
48. Tsujimoto Y and Shimizu S: VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ 7: 1174-1181, 2000. (Pubitemid 32042224)
49. Gollapudi S, McCormick MJ and Gupta S: Changes in mitochondrial membrane potential and mitochondrial mass occur independent of the activation of caspase-8 and caspase-3 during CD95-mediated apoptosis in peripheral blood T cells. Int J Oncol 22: 597-600, 2003.
50. Wu Y, Shang Y, Sun SG, Liu RG and Yang WQ: Protective effect of erythropoietin against 1-methyl-4-phenylpyridinium-induced neurodegenaration in PC12 cells. Neurosci Bull 23: 156-164, 2007. (Pubitemid 47104870)
51. Shay KP, Moreau RF, Smith EJ, Smith AR and Hagen TM: Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 1790: 1149-1160, 2009.
52. Coleman MD, Eason RC and Bailey CJ: The therapeutic use of lipoic acid in diabetes: a current perspective. Environ Toxicol Pharmacol 10: 167-172, 2001. (Pubitemid 32831509)
53. Panigrahi M, Sadguna Y, Shivakumar BR, et al: alpha-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats. Brain Res 717: 184-188, 1996. (Pubitemid 26153450)
54. Arivazhagan P, Shila S, Kumaran S and Panneerselvam C: Effect of DL-alpha-lipoic acid on the status of lipid peroxidation and antioxidant enzymes in various brain regions of aged rats. Exp Gerontol 37: 803-811, 2002. (Pubitemid 34518498)